Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 21, 2014; 20(27): 9072-9089
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9072
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9072
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age?
Gábor Firneisz, 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary
Author contributions: Firneisz G contributed solely to this manuscript.
Correspondence to: Gábor Firneisz, MD, PhD, 2nd Department of Internal Medicine, Semmelweis University, Szentkiralyi St 46, H-1088 Budapest, Hungary. firneisz.gabor@med.semmelweis-univ.hu
Telephone: +36-1-2100278-5520 Fax: +36-1-2661007
Received: November 14, 2013
Revised: March 20, 2014
Accepted: May 12, 2014
Published online: July 21, 2014
Processing time: 250 Days and 0.3 Hours
Revised: March 20, 2014
Accepted: May 12, 2014
Published online: July 21, 2014
Processing time: 250 Days and 0.3 Hours
Core Tip
Core tip: In this review article, non-alcoholic fatty liver disease (NAFLD) spectrum disease is discussed in detail. The epidemiology of NAFLD/nonalcoholic steatohepatitis and the relationship of NAFLD to different forms of diabetes mellitus including type 2 diabetes mellitus and gestational diabetes mellitus are reviewed. Attention is paid to the main biochemical events, to dysfunctional adipose tissue and visceral adiposity associated with NAFLD and insulin resistance, to mitochondrial dysfunction and to the role of the entero-insular axis in NAFLD. Genetics and potential pharmacological approaches are discussed.